Pharming Group vs Sinovac Biotech
Pharming Group and Sinovac Biotech are similar in size: $376m and $386m of revenue in their latest fiscal years. Pharming Group grew faster (26.6% against 6.8%). Pharming Group kept more of each dollar of sales as profit: a net margin of 0.8% against -15.5%. Sinovac Biotech carries less debt relative to equity (11.1% against 35.4%).
| Latest fiscal year | Pharming GroupPHAR, 2025 | Sinovac BiotechSVA, 2025 |
|---|---|---|
| Revenue | $376m | $386m |
| Revenue growth | 26.6% | 6.8% |
| Net income | $2.9m | −$59.7m |
| Operating margin | 6.9% | -127.0% |
| Net margin | 0.8% | -15.5% |
| Return on equity | 1.1% | -0.9% |
| Free cash flow | $54.0m | −$561m |
| Cash | $145m | $488m |
| Total debt | $98.1m | $495m |
| Debt to equity | 35.4% | 11.1% |
| Dividend per share | — | — |
| Dividend yield | — | 760.2% |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $898m | $465m |
| Price vs our value range | Above our value range | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |